Developing global, high-value products for patients with significant unmet medical needs in niche indications
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
IPO Calliditas Therapeutics
On February 7, 2019 Calliditas Therapeutics published its business update for the full-year 2018.
Calliditas Therapeutics AB
SE-111 24 Stockholm
Company number: 556659-9766
© Calliditas Therapeutics AB 2019